Gordon Sussman
Overview
Explore the profile of Gordon Sussman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metz M, Gimenez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, et al.
N Engl J Med
. 2025 Mar;
392(10):984-994.
PMID: 40043237
Background: Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral, highly...
2.
Pongracic J, Gagnon R, Sussman G, Siri D, Oriel R, Brown-Whitehorn T, et al.
J Allergy Clin Immunol Pract
. 2025 Mar;
PMID: 40023371
Background: Due to limited treatment options for peanut allergy, patients remain at risk for allergic reactions due to accidental exposure. Epicutaneous immunotherapy (EPIT) is a novel treatment being investigated for...
3.
Nair A, Leon-Ponte M, Kim V, Sussman G, Ehrhardt G, Grunebaum E
Front Immunol
. 2024 Nov;
15:1451232.
PMID: 39575239
Introduction: CD38 is an ectoenzyme receptor found on hematopoietic cells and its expression is used in the flow cytometric analysis of sub-populations of circulating B cells among peripheral blood mononuclear...
4.
Conway A, Verdi M, Shaker M, Bernstein J, Beamish C, Morse R, et al.
J Allergy Clin Immunol Pract
. 2024 Mar;
12(7):1738-1750.
PMID: 38499084
Allergist-immunologists face significant challenges as experts in an ever-evolving field of neuroimmunology. Among these challenges is the increasingly frequent need to counsel patients with suspected mast cell activation disorders about...
5.
Rubeiz C, Asero R, Betschel S, Craig T, Grumach A, Hide M, et al.
World Allergy Organ J
. 2024 Jan;
17(1):100858.
PMID: 38235261
Background: Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally. Objective: This study was performed to determine...
6.
Maurer M, Ensina L, Gimenez-Arnau A, Sussman G, Hide M, Saini S, et al.
Lancet
. 2023 Nov;
403(10422):147-159.
PMID: 38008109
Background: Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms...
7.
Davis C, Lange L, Beyer K, Fleischer D, Ford L, Sussman G, et al.
J Allergy Clin Immunol Glob
. 2023 Oct;
2(1):69-75.
PMID: 37780103
Background: Co-occurring atopic conditions are common in children with peanut allergy. As such, it is important to examine the safety and efficacy of epicutaneous immunotherapy with Viaskin Peanut 250 μg...
8.
Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C, et al.
Clin Transl Allergy
. 2023 Sep;
13(9):e12299.
PMID: 37746794
Introduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a...
9.
Monino-Romero S, Kolkhir P, Szepfalusi Z, Schoepke N, Metz M, Asero R, et al.
Clin Transl Allergy
. 2023 Jul;
13(7):e12272.
PMID: 37488737
No abstract available.
10.
Metz M, Bernstein J, Gimenez-Arnau A, Hide M, Maurer M, Sitz K, et al.
World Allergy Organ J
. 2022 Nov;
15(11):100716.
PMID: 36440464
Background: Disease burden is particularly high in Chronic Spontaneous Urticaria (CSU) patients with angioedema, and patients whose signs and symptoms are inadequately controlled by H-antihistamines need new treatment options. Here...